Loading…
Manufactures active pharmaceutical ingredients and formulations for regulated markets, demerged from Strides Pharma Science.
Manufactures active pharmaceutical ingredients and formulations for regulated markets, demerged from Strides Pharma Science.
In one line: A regulated-market API/formulations exporter.
Moat: narrow (regulatory licence). US FDA/EU-approved manufacturing plants support long-term regulated market supply contracts.
Headquarters: Bengaluru, India · Employees: 3,950
Size Alivus Life Sciences (ALIVUS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.92B, the 379th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,481 on 6 Nov 2026.
Performance Over six months the shares gained 32.1%, against -8.7% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 8.2% over the last twelve months (peer median +11.2%); the operating margin is 31.3% (peer median 12.3%).
Valuation It trades at 24.4× forward earnings against a peer median of 20.4× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 10.8 points above its cost of capital (12.7% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹26.8B | ₹25.4B | ₹23.7B | ₹22.7B | ₹21.5B |
| Revenue growth | — | +7% | +4% | +6% | — |
| Gross profit | ₹12.7B | ₹8.77B | ₹7.64B | ₹7.40B | ₹7.11B |
| EBITDA | ₹9.23B | ₹7.95B | ₹6.82B | ₹6.74B | ₹6.39B |
| Net income | ₹6.70B | ₹5.64B | ₹4.86B | ₹4.71B | ₹4.67B |
| Free cash flow | n/a | ₹2.59B | ₹2.45B | ₹2.97B | ₹1.59B |
| Capital expenditure | n/a | ₹3.07B | ₹1.66B | ₹1.29B | ₹1.70B |
| Total debt | ₹529M | ₹568M | ₹566M | ₹171M | ₹194M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alivus Life Sciences ALIVUS.NS | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% |
| Strides Pharma Science STAR.NS | $973M | -13% | +11% | 14% | 15.5× | 18.1% |
| Aurobindo Pharma AUROPHARMA.NS | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% |
| Cipla CIPLA.NS | $12.1B | +4% | -1% | 13% | 29.0× | 28.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALIVUS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.1% | -1.7% | 5th highest of 21 |
| 6-month return | +32.1% | -8.7% | 3rd highest of 21 |
| Distance from 52-week high | -4.2% | -27.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +8.2% | +11.2% | 10th lowest of 21 |
| Operating margin | 31.3% | 12.3% | 4th highest of 21 |
| Forward P/E | 24.4× | 20.4× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 20.4% | 9.1% | 5th most demanding of 18 |
| Growth delivered (Del g) | +6.2% | +7.8% | 7th lowest of 18 |
| Hurdle (Req g minus delivered) | +14.2 pp | -0.2 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | +10.8 pp | -0.4 pp | 5th highest of 21 |
| EV / EBITDA | 18.7× | 14.7× | 4th most expensive of 9 |
| Net debt / EBITDA | -1.0× | -0.2× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.89B | -18% | -1% | 8% | 8.3× | 0.4% | -0.2% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |